| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1036269702 |
| P356 | DOI | 10.1186/S12967-014-0243-9 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1186/s12967-014-0243-9 |
| P932 | PMC publication ID | 4163166 |
| P698 | PubMed publication ID | 25182194 |
| P5875 | ResearchGate publication ID | 265299158 |
| P2093 | author name string | Noor Hayaty Abu Kasim | |
| Thamil Selvee Ramasamy | |||
| Thekkeparambil Chandrabose Srijaya | |||
| P2860 | cites work | Effects of Adipose Tissue-Derived Stem Cell Therapy After Myocardial Infarction: Impact of the Route of Administration | Q59296594 |
| Treat the graft to improve the regenerative ability of the host | Q59331539 | ||
| Immunological reconstitution of sex-linked lymphopenic immunological deficiency | Q70099373 | ||
| A double-blinded evaluation of propacetamol versus ketorolac in combination with patient-controlled analgesia morphine: analgesic efficacy and tolerability after gynecologic surgery | Q74594954 | ||
| Autologous bone marrow transplantation in patients with subacute and chronic spinal cord injury | Q79705120 | ||
| Preconditioning enhances cell survival and differentiation of stem cells during transplantation in infarcted myocardium | Q79842788 | ||
| Two steps to functional mesenchymal stromal cells for clinical application | Q80681229 | ||
| Tapping the potential of fixed-dose combinations | Q80834515 | ||
| Routes of stem cell administration in the adult rodent | Q80965707 | ||
| Coadministration of endothelial and smooth muscle progenitor cells enhances the efficiency of proangiogenic cell-based therapy | Q81820346 | ||
| Adult stem cells--perspectives in treatment of metabolic diseases | Q82353922 | ||
| Emerging therapy for improving wound repair of severe radiation burns using local bone marrow-derived stem cell administrations | Q82550731 | ||
| Safety and feasibility of transendocardial autologous bone marrow cell transplantation in patients with advanced heart disease | Q82727493 | ||
| Myocardial protection by pioglitazone, atorvastatin, and their combination: mechanisms and possible interactions | Q83128310 | ||
| Gene therapy | Q83198437 | ||
| Preconditioning by mitochondrial reactive oxygen species improves the proangiogenic potential of adipose-derived cells-based therapy | Q83787143 | ||
| Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study | Q84586351 | ||
| Gender-related differences in pharmacokinetics and pharmacodynamics | Q46484992 | ||
| Enhanced cardioprotection against ischemia-reperfusion injury with combining sildenafil with low-dose atorvastatin | Q46910494 | ||
| Mesenchymal stem cell concentration and bone repair: potential pitfalls from bench to bedside | Q47893500 | ||
| Nasal administration of stem cells: a promising novel route to treat neonatal ischemic brain damage. | Q48122882 | ||
| Anaesthesia, critical care, and pain in the 21st century: the first decade | Q48254123 | ||
| Direct intramyocardial mesenchymal stromal cell injections in patients with severe refractory angina: one-year follow-up. | Q48459462 | ||
| Autologous bone marrow-derived cultured mesenchymal stem cells delivered in a fibrin spray accelerate healing in murine and human cutaneous wounds. | Q48910075 | ||
| Intravenous autologous bone marrow mononuclear cells for ischemic stroke. | Q49015926 | ||
| Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis. | Q50640546 | ||
| Experimental and clinical regenerative capability of human bone marrow cells after myocardial infarction. | Q51618016 | ||
| Drug preferences in humans. | Q52289576 | ||
| Administration of autologous bone marrow stem cells into spinal cord injury patients via multiple routes is safe and improves their quality of life: comprehensive case studies. | Q53163674 | ||
| [Enhancement of the anti-ischemic kidney resistance by adaptive hypoxic conditioning and drug therapy]. | Q54097828 | ||
| Preconditioning mesenchymal stem cells with transforming growth factor-alpha improves mesenchymal stem cell-mediated cardioprotection. | Q54705013 | ||
| Generation of Induced Pluripotent Stem Cells Using Recombinant Proteins | Q56999795 | ||
| Clinical applications of mesenchymal stem cells | Q21198864 | ||
| Pharmacogenetics, pharmacogenomics, and individualized medicine | Q23919667 | ||
| Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine | Q24632756 | ||
| Advanced therapies using autologous bone marrow cells for chronic liver disease | Q26830651 | ||
| Can pluripotent stem cells be used in cell-based therapy? | Q27002327 | ||
| Sipuleucel-T immunotherapy for castration-resistant prostate cancer | Q27860648 | ||
| Physico-chemical characteristics of lipoplexes influence cell uptake mechanisms and transfection efficacy | Q28475692 | ||
| A ROCK inhibitor permits survival of dissociated human embryonic stem cells | Q29616183 | ||
| Generation of induced pluripotent stem cells using recombinant proteins | Q29619162 | ||
| Paracrine mechanisms in adult stem cell signaling and therapy | Q29620571 | ||
| Embryonic stem cell trials for macular degeneration: a preliminary report | Q29620714 | ||
| Noninvasive pulsed focused ultrasound allows spatiotemporal control of targeted homing for multiple stem cell types in murine skeletal muscle and the magnitude of cell homing can be increased through repeated applications | Q30427305 | ||
| Valproic acid confers functional pluripotency to human amniotic fluid stem cells in a transgene-free approach | Q30525523 | ||
| Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans | Q31113632 | ||
| Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing | Q33326623 | ||
| Graft failure in the modern era of allogeneic hematopoietic SCT. | Q33404733 | ||
| Route of delivery and baseline left ventricular ejection fraction, key factors of bone-marrow-derived cell therapy for ischaemic heart disease | Q33490304 | ||
| Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta | Q33855709 | ||
| Clinical trials for stem cell therapies | Q33898451 | ||
| Targeting of mesenchymal stem cells to ovarian tumors via an artificial receptor | Q33907262 | ||
| Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: umbilical cord blood is a feasible option for patients without HLA-matched sibling donors | Q33937055 | ||
| Effect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantation | Q34033553 | ||
| Reversible and noisy progression towards a commitment point enables adaptable and reliable cellular decision-making | Q34079142 | ||
| Therapeutic cell engineering with surface-conjugated synthetic nanoparticles | Q34112602 | ||
| Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study | Q34132522 | ||
| Stem cell therapy in perspective | Q34179220 | ||
| Stromal cell-derived factor-1 (SDF-1): homing factor for engineered regenerative medicine. | Q37827159 | ||
| Clonal interrogation of stem cells | Q37859624 | ||
| Optimizing intravenous drug administration by applying pharmacokinetic/pharmacodynamic concepts. | Q37882230 | ||
| Immuno-imaging using nanobodies | Q37897404 | ||
| Introduction to induced pluripotent stem cells: advancing the potential for personalized medicine | Q37944035 | ||
| Strategies for improved targeting of therapeutic cells: implications for tissue repair. | Q38004359 | ||
| Preconditioning approach in stem cell therapy for the treatment of infarcted heart | Q38037189 | ||
| Application of MultiStem(®) Allogeneic Cells for Immunomodulatory Therapy: Clinical Progress and Pre-Clinical Challenges in Prophylaxis for Graft Versus Host Disease | Q38064454 | ||
| Preconditioning strategy in stem cell transplantation therapy | Q38126494 | ||
| Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies | Q38130382 | ||
| Current and future approaches to treat graft failure after allogeneic hematopoietic stem cell transplantation | Q38155240 | ||
| Preconditioned stem cells: a promising strategy for cell-based ischemic stroke therapy | Q38222250 | ||
| Development of a peptide-targeted, myocardial ischemia-homing, mesenchymal stem cell | Q38436187 | ||
| Application of three-dimensional culture conditions to human embryonic stem cell-derived definitive endoderm cells enhances hepatocyte differentiation and functionality | Q39273051 | ||
| A double-blind placebo-controlled clinical evaluation of MultiStem for the treatment of ischemic stroke | Q39414868 | ||
| Hypoxic preconditioning increases gap-junctional graft and host communication | Q39645512 | ||
| Preconditioning by toll-like receptor 2 agonist Pam3CSK4 reduces CXCL1-dependent leukocyte recruitment in murine myocardial ischemia/reperfusion injury | Q39750933 | ||
| Ixmyelocel-T, an expanded multicellular therapy, contains a unique population of M2-like macrophages | Q39828591 | ||
| CXCR4 chemokine receptor engagement modifies integrin dependent adhesion of renal carcinoma cells | Q40092108 | ||
| Sex differences in pharmacokinetics and pharmacodynamics | Q40398634 | ||
| Isolation of primitive endoderm, mesoderm, vascular endothelial and trophoblast progenitors from human pluripotent stem cells. | Q41514993 | ||
| Allogenicity & immunogenicity in regenerative stem cell therapy | Q41964852 | ||
| Mesenchymal stem cells: From bench to bedside | Q42133000 | ||
| Mechanisms of cell therapy for clinical investigations: an urgent need for large-animal models | Q42918845 | ||
| Which is the most suitable and effective route of administration for mesenchymal stem cell-based immunomodulation therapy in experimental kidney transplantation: endovenous or arterial? | Q43037503 | ||
| Ethical considerations in the application of preconditioning to solid organ transplantation | Q43076794 | ||
| Pharmacological preconditioning of mesenchymal stem cells with trimetazidine (1-[2,3,4-trimethoxybenzyl]piperazine) protects hypoxic cells against oxidative stress and enhances recovery of myocardial function in infarcted heart through Bcl-2 express | Q43141698 | ||
| Analysis of different routes of administration of heterologous 5-azacytidine-treated mesenchymal stem cells in a porcine model of myocardial infarction | Q43284008 | ||
| Cell therapy companies make strong progress from October 2012 to March 2013 amid mixed stock market sentiment | Q43408349 | ||
| Human marrow stromal cell therapy for stroke in rat: neurotrophins and functional recovery | Q44115092 | ||
| Case control series of intrathecal autologous bone marrow mesenchymal stem cell therapy for chronic spinal cord injury. | Q44487129 | ||
| Effects of MSC coadministration and route of delivery on cord blood hematopoietic stem cell engraftment | Q44953364 | ||
| Individual differences in the reinforcing and subjective effects of amphetamine and diazepam | Q45024550 | ||
| Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. | Q45958600 | ||
| Astroglial cytoprotection by erythropoietin pre-conditioning: implications for ischemic and degenerative CNS disorders | Q46427106 | ||
| Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells | Q34321823 | ||
| Pharmacologic preconditioning: translating the promise | Q34440453 | ||
| Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation | Q34616704 | ||
| Grafting of human bone marrow stromal cells into spinal cord injury: a comparison of delivery methods. | Q34776506 | ||
| Ischaemic preconditioning and outcomes after angioplasty: effects of drug therapy | Q35039855 | ||
| The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activity | Q35073652 | ||
| Engineered cell homing | Q35623682 | ||
| Role of stem cells in cancer therapy and cancer stem cells: a review | Q35846826 | ||
| Analysis of risk factors influencing outcome in children with myelodysplastic syndrome after unrelated cord blood transplantation. | Q36002278 | ||
| Cell-based cardiovascular repair--the hurdles and the opportunities | Q36291654 | ||
| Catheter-based delivery of cells to the heart | Q36406473 | ||
| Augmentation of neovascularization [corrected] in hindlimb ischemia by combined transplantation of human embryonic stem cells-derived endothelial and mural cells | Q36462870 | ||
| Adult stem cells in the treatment of autoimmune diseases | Q36508132 | ||
| Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial | Q36603453 | ||
| A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction | Q36634299 | ||
| Stem cells in cutaneous wound healing | Q36727405 | ||
| PTEN, the Achilles' heel of myocardial ischaemia/reperfusion injury? | Q36733630 | ||
| Stem cells for the treatment of spinal cord injury. | Q36976377 | ||
| Cell-based therapy of myocardial infarction | Q36977051 | ||
| Stem cells and cancer: an overview | Q36979034 | ||
| Towards therapeutic application of ocular stem cells. | Q36981014 | ||
| Cell-based therapy for myocardial ischemia and infarction: pathophysiological mechanisms. | Q37014724 | ||
| Graft failure after allogeneic hematopoietic cell transplantation | Q37045988 | ||
| Stem cells and neurological diseases. | Q37053159 | ||
| The therapeutic potential of stem cells in heart disease | Q37053163 | ||
| Human embryonic stem cells and liver diseases: from basic research to future clinical application | Q37077702 | ||
| Nonunions and the potential of stem cells in fracture-healing | Q37091547 | ||
| The stem cell movement. | Q37170616 | ||
| Cardiac stem cells with electrical stimulation improve ischaemic heart function through regulation of connective tissue growth factor and miR-378 | Q37232168 | ||
| A systematic review and empirical analysis of the relation between dose and duration of drug action | Q37606934 | ||
| Mechanisms involved in the therapeutic properties of mesenchymal stem cells | Q37635499 | ||
| Origins and implications of pluripotent stem cell variability and heterogeneity | Q37693830 | ||
| Preconditioning and stem cell survival | Q37766195 | ||
| Umbilical cord blood transplantation for thalassemia major | Q37809341 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | point-of-care system | Q64733592 |
| stem cell transplantation | Q65592366 | ||
| pharmacotherapy | Q701216 | ||
| P304 | page(s) | 243 | |
| P577 | publication date | 2014-09-04 | |
| P1433 | published in | Journal of Translational Medicine | Q15716664 |
| P1476 | title | Advancing stem cell therapy from bench to bedside: lessons from drug therapies | |
| P478 | volume | 12 |
| Q49501063 | 3D-cultured adipose tissue-derived stem cells inhibit liver cancer cell migration and invasion through suppressing epithelial-mesenchymal transition. |
| Q36728564 | A Detailed Assessment of Varying Ejection Rate on Delivery Efficiency of Mesenchymal Stem Cells Using Narrow-Bore Needles. |
| Q58610536 | Adipose Stem Cell Translational Applications: From Bench-to-Bedside |
| Q36987494 | Adipose-Derived Regenerative Cell Therapy for Burn Wound Healing: A Comparison of Two Delivery Methods |
| Q47850302 | All-trans retinoic acid preconditioning enhances proliferation, angiogenesis and migration of mesenchymal stem cell in vitro and enhances wound repair in vivo |
| Q64922663 | Bone marrow-derived lineage-negative cells accelerate skin regeneration in vivo. |
| Q48666847 | Bone-healing capacity of conditioned medium derived from three-dimensionally cultivated human mesenchymal stem cells and electrical stimulation on collagen sponge. |
| Q38840851 | Current Understanding of the Pathways Involved in Adult Stem and Progenitor Cell Migration for Tissue Homeostasis and Repair |
| Q47873444 | Cytoprotective effects of endothelin-1 on mesenchymal stem cells: an in vitro study. |
| Q51748839 | Development of Controlled Drug Delivery Systems for Bone Fracture-Targeted Therapeutic Delivery: A Review. |
| Q55065461 | Donor variability among anti-inflammatory pre-activated mesenchymal stromal cells. |
| Q46054367 | Exploiting Heparan Sulfate Proteoglycans in Human Neurogenesis-Controlling Lineage Specification and Fate |
| Q48534103 | Fasudil Enhances Therapeutic Efficacy of Neural Stem Cells in the Mouse Model of MPTP-Induced Parkinson's Disease. |
| Q36257063 | From bench to bedside: use of human adipose-derived stem cells. |
| Q92656928 | Human induced pluripotent stem cell-derived extracellular vesicles reduce hepatic stellate cell activation and liver fibrosis |
| Q64968451 | Insights into Inflammatory Priming of Adipose-Derived Mesenchymal Stem Cells: Validation of Extracellular Vesicles-Embedded miRNA Reference Genes as A Crucial Step for Donor Selection. |
| Q41104509 | Intracoronary Administration of Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells Improves Myocardial Perfusion But Not Left Ventricle Function, in a Translational Model of Acute Myocardial Infarction. |
| Q38342080 | Intranasal delivery of stem cells as therapy for central nervous system disease |
| Q38804309 | Local and targeted drug delivery for bone regeneration |
| Q47284038 | Maximizing neotissue growth kinetics in a perfusion bioreactor: An in silico strategy using model reduction and Bayesian optimization |
| Q38733373 | Mesenchymal stromal cell therapy for the treatment of intestinal ischemia: Defining the optimal cell isolate for maximum therapeutic benefit |
| Q52314577 | Pluripotent Stem Cells for Retinal Tissue Engineering: Current Status and Future Prospects. |
| Q38577907 | Prolyl hydroxylase inhibitors act as agents to enhance the efficiency of cell therapy |
| Q58659464 | Science, ethics and communication remain essential for the success of cell-based therapies |
| Q28069890 | Secreted trophic factors of mesenchymal stem cells support neurovascular and musculoskeletal therapies |
| Q26782194 | Stem cells: An eventual treatment option for heart diseases |
| Q53476373 | Translational considerations in injectable cell-based therapeutics for neurological applications: concepts, progress and challenges. |
Search more.